| Ytd | 50.24% | |
| 1y | 9.38% |
| Open | 0.74 | Prev Close | 0.74 | Low | 0.73 | High | 0.78 | Mkt Cap | 15.15M |
| Vol | 450.40K | Avg Vol | 317.90K | EPS | -1.13 | P/E | -0.67 | Forward P/E | -1.16 |
| Beta | -0.31 | Short Ratio | 2.03 | Inst. Own | 3.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 0.71 | 200-d Avg | 0.73 | 1yr Est | 8.88 |
LGVN News
MIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage rege
MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnolo
Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy fo
Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC) entitled “La
Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech s
Longeveron Inc. (LGVN) Shareholder/Analyst Call Prepared Remarks Transcript
Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's
MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnol
MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnol
Longeveron will present at BIO 2026. CEO, CFO & BD will host meetings to explore partnership opportu
MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnolo
Longeveron Inc. (LGVN) Q1 2026 Earnings Call Transcript
On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromes
Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLH
MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerativ
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnolo
Longeveron (NASDAQ: LGVN - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disea
China National Intellectual Property Administration has granted a patent covering potency assay meth
Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript
Longeveron reported financial results for the year ended December 31, 2025 and provided a business u
Tuesday's move higher precedes an earnings print where analysts are looking for an EPS loss of 38 ce
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly los
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company
On Thursday, 369 companies hit new 52-week lows.
During Tuesday's session, 275 companies made new 52-week lows.
On Wednesday, 179 companies reached new 52-week lows.
During Friday's trading, 293 companies set new 52-week lows.